Clinical Trial Detail

NCT ID NCT01928394
Title A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Bristol-Myers Squibb
Indications

Her2-receptor negative breast cancer

stomach cancer

pancreatic cancer

lung small cell carcinoma

urinary bladder cancer

Therapies

Ipilimumab

Nivolumab

Age Groups: adult

Additional content available in CKB BOOST